Nexavar approved for patients with inoperable liver cancer
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. – The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.